In the realm of modern drug discovery technologies, fragment-based approaches and virtual ligand screening are emerging alternative approaches to high-throughput screening (HTS). For as simple as it sounds, a hybrid approach in which fragments are discovered first in silico may be an unbeatable route to hit identification for some drug targets.
This is a preview of subscription content, log in via an institution to check access.
Katie Vicari
References
Jahnke, W. & Erlanson, D.A. (eds.). Fragment-based Approaches in Drug Discovery (Wiley-VCH, Weinheim, Germany, 2006).
Hajduk, P.J. & Greer, J. Nat. Rev. Drug Discov. 6, 211–219 (2007).
Rees, D.C., Congreve, M., Murray, C.W. & Carr, R. Nat. Rev. Drug Discov. 3, 660–672 (2004).
Pellecchia, M. et al. Nat. Rev. Drug Discov. 7, 738–745 (2008).
Shoichet, B.K. Nature 432, 862–865 (2004).
Chen, Y. & Shoichet, B.K. Nat. Chem. Biol. 5, 358–364 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pellecchia, M. Fragment-based drug discovery takes a virtual turn. Nat Chem Biol 5, 274–275 (2009). https://doi.org/10.1038/nchembio0509-274
Issue Date:
DOI: https://doi.org/10.1038/nchembio0509-274
- Springer Nature America, Inc.
This article is cited by
-
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation
Nature Chemistry (2015)
-
Retrospective molecular docking study of WY-25105 ligand to β-secretase and bias of the three-dimensional structure flexibility
Journal of Molecular Modeling (2013)